Ghost Tree Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Ghost Tree Capital’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-100,000	Closed	-$5.99M	–	74
2023 Q4	$5.99M	Sell	100,000 -85,000	-46%	-$4.31M	1.96%	15
2023 Q3	$7.04M	Buy	+185,000	New	+$8.13M	2.31%	14
2023 Q2	–	Sell	-51,900	Closed	-$3.42M	–	60
2023 Q1	$3.42M	Buy	+51,900	New	+$2.99M	1.01%	35
2021 Q4	–	Sell	-150,000	Closed	-$4.94M	–	51
2021 Q3	$4.94M	Buy	+150,000	New	+$8.43M	1.45%	25
2020 Q1	–	Sell	-250,000	Closed	-$7.66M	–	49
2019 Q4	$7.66M	Buy	+250,000	New	+$6.92M	1.46%	26

Other funds holding APLS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Ghost Tree Capital's APLS Position: Q3 2024 in Review

Ghost Tree Capital reduced its Apellis Pharmaceuticals (APLS) stake by 52% in Q3 2024, selling an estimated $2.59M and leaving 65,000 shares worth $1.87M. The position accounts for 0.57% of the portfolio, ranked #46.

Ghost Tree Capital first reported a position in APLS in Q2 2018 and has held it in 16 quarters since. The position peaked at $18.8M in Q3 2022. 265 funds tracked by Wall St. Rank hold APLS as of Q3 2024.

Ghost Tree Capital held 65,000 shares of Apellis Pharmaceuticals worth $1.87M as of Q3 2024.
Ghost Tree Capital sold 70,000 Apellis Pharmaceuticals shares in Q3 2024, an estimated $2.59M.
Apellis Pharmaceuticals made up 0.57% of Ghost Tree Capital's portfolio in Q3 2024, its #46 holding.
Ghost Tree Capital first reported a position in Apellis Pharmaceuticals in Q2 2018 and has held it in 16 quarters since.
Ghost Tree Capital's Apellis Pharmaceuticals position peaked at $18.8M in Q3 2022.
265 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.